LA-URSHALAR BROCK: Open Payments
NPI 1073764981 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$938 in 9 payments from 5 companies in 2025. Trend: 2023 $125 · 2024 $3,551 · 2025 $938
Food & beverage: $648Consulting: $290
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $315 |
| Daiichi Sankyo Inc. | 1 | $290 |
| AstraZeneca Pharmaceuticals LP | 2 | $164 |
| Stemline Therapeutics Inc. | 1 | $85 |
| Novartis Pharmaceuticals Corporation | 1 | $83 |
Products named: Trodelvy, DATROWAY, ENHERTU, Orserdu, KISQALI.
Industry payments across GA — which companies pay providers there.
